AUTHOR=Zhang Chen , Zhang Dandan , Tang Lijun , Tian Feng 

TITLE=Research on a machine learning method for predicting discharge time of thyroid cancer patients receiving 131I treatment: a retrospective study

JOURNAL=Frontiers in Physiology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1599657

DOI=10.3389/fphys.2025.1599657

ISSN=1664-042X

ABSTRACT=Radioactive iodine-131 (131I) based internal irradiation therapy has become one of the main methods for treating thyroid cancer, but patient usually need to be hospitalized after taking 131I until the residual activity meets the discharge criteria. However, the complex metabolism of 131I drug in individualized patient may make it difficult to assess when patients would meet discharge criteria, thereby increasing the hospital stay. In this study, some basic data of 1,044 thyroid cancer patients received 131I treatment at the First Affiliated Hospital with Nanjing Medical University from January 2022 to January 2024 are collected. Numerical analysis methods are used to analyze the absorption and metabolism of 131I drug in different patients and support vector machine (SVM) model is used to predict the discharge time of different patients. Results show that the effective half-life of 131I in both male and female patients are 10.35 h and 9.64 h, whose residual activity less than 400 MBq after 48 h of taking 131I. While the effective half-life of 131I in both male and female patients are 14.07 and 13.47 h for that the residual activity are greater than 400 MBq after 48 h of taking 131I. Furthermore, a discharge time prediction method based on SVM has been developed and the accuracy and precision of this method in predicting whether a patient could be discharged from the hospital after 48 h of taking the 131I drug are 88.04% and 96.89%. These results show that the discharge time prediction method could be expected to improve the rotation efficiency of nuclear medicine wards and provide timely treatment for more thyroid cancer patients receiving 131I treatment in the future.